Scientists discover biomarkers associated with acute, chronic phases of TBI

By Greg Slabodkin, ScienceBoard Editor in Chief

July 25, 2022 -- Arizona State University (ASU) scientists have provided some of the first detailed view of the molecular and cellular mechanisms behind traumatic brain injury (TBI) as the condition progresses from the acute to the chronic phase.

Researchers utilized a mouse model for their study, published on July 22 in in the journal Science Advances, to help uncover the root causes of TBI by identifying biomarkers that could pave the way for the design of much-needed diagnostics and therapeutics.

The molecular and cellular mechanisms of TBI injury progression are multifaceted and complex which "affects the development of diagnostic and treatment options" including targeted drug delivery, according to Sarah Stabenfeldt, PhD, the study's corresponding author and professor at ASU.

"The neurotrauma research community is a well-established field that has developed and characterized preclinical animal models to better understand TBI pathology and assess the efficacy of therapeutic interventions," Stabenfeldt said in a statement. "Using the established mouse model enabled us to conduct biomarker discover where the complexity and evolution of the injury pathology was progressing."

Researchers used what they contend is a "unique discovery pipeline" to identify novel targeting motifs that recognize specific temporal phases of TBI pathology. The pipeline combined in vivo biopanning with domain antibody (dAb) phage display, next-generation sequencing (NGS) analysis, and peptide synthesis.

"Our study leverages the sensitivity and specificity of phage to discover novel targeting motifs," Stabenfeldt said. "The combination of phage and NGS has been used previously, thereby leveraging bioinformatic analysis. The unique contribution of our study is putting all of these tools together specifically for an in vivo model of TBI."

The scientists found a suite of unique biomarkers specifically associated with the acute or chronic phases of TBI. In the acute phase, TBI targeting motif recognized targets associated with mainly metabolic and mitochondrial dysfunction, while the chronic TBI motif was largely associated with neurodegenerative processes.

In the study, proteins involved in neurodegenerative diseases were not detected at one day post-injury but were detected at seven days post-injury. This phenomenon may help to explain why people who have had a TBI are more susceptible to developing later in life neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, according to the researchers.

Leveraging this successful discovery pipeline can serve as the foundation for next-generation targeted TBI therapeutics and diagnostics, the researchers contend. Going forward, they plan to collaborate with ASU clinical partners and expand their research to human samples.

Whole blood exchange reduces formation of amyloid plaque in brains of mice
University of Texas Health Science Center at Houston researchers performed a series of whole blood exchange treatments to partially replace blood from...
Scientists able to visualize mRNA molecules in brains of living mice
A team of researchers has developed a new imaging technique that gives scientists a real-time view into mRNA synthesis and gene expression in the brain...
Scientists discover novel mechanism by which neurons, glia collaborate
Champalimaud Foundation scientists have discovered a novel mechanism by which neurons and glia collaborate to drive neural regeneration following brain...
Creating an opening for treatments into the brains of mice
The cellular barrier that protects the brain also has the unfortunate effect of preventing medical treatments from reaching areas of the brain where they...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter